Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Outcomes of donation after circulatory death heart transplantation in recipients with pulmonary hypertension.

The Journal of thoracic and cardiovascular surgery·2026
Same author

Erratum to 2025 American Association for Thoracic Surgery (AATS) Expert Consensus Document: Surgical management of acute myocardial infarction and associated complications: The Journal of Thoracic and Cardiovascular Surgery, Volume 170, Issue 5, 2025, Pages 1327-1344.

The Journal of thoracic and cardiovascular surgery·2026
Same author

Surgical or transcatheter mitral valve replacement with mitral annular calcification.

JTCVS structural and endovascular·2026
Same author

Quantifying sleep wake rhythms in the hospital environment with digital technologies.

NPJ digital medicine·2026
Same author

Immediate Postoperative Pacing Dependency Is Not Associated With Worse Mid-Term Survival in Redo Mitral Valve Surgery.

The American journal of cardiology·2026
Same author

Cost-Effectiveness of Valve-in-Valve Transcatheter Mitral Valve Replacement Versus Redo Surgical Mitral Valve Replacement for Degenerated Bioprosthetic Mitral Valve.

Structural heart : the journal of the Heart Team·2026

相关实验视频

Updated: Jul 6, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

循环素A2的治疗剂量诱导心肌再生,并在缺血性心力衰竭中增强心脏功能.

Y Joseph Woo1, Corinna M Panlilio, Richard K Cheng

  • 1Division of Cardiothoracic Surgery, Department of Surgery, University of Pennsylvania School of Medicine, 3400 Spruce St, Philadelphia PA 19104, USA. wooy@uphs.upenn.edu

Circulation
|July 6, 2006
PubMed
概括

赛克林A2基因疗法通过激活心肌细胞分裂促进心脏再生,从而改善心脏功能和增加大鼠肌纤维密度. 这为心力衰竭提供了潜在的新疗法.

更多相关视频

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

相关实验视频

Last Updated: Jul 6, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

科学领域:

  • 心血管生物学 心血管生物学
  • 再生医学是一种再生医学.
  • 基因治疗 基因治疗

背景情况:

  • 心力衰竭是一个重要的全球健康问题.
  • 目前的治疗方法有限,需要新的治疗策略.
  • 内源性心肌再生是一种有前途的方法.

研究的目的:

  • 为了研究cyclin A2 (细胞循环调节剂) 在诱导心肌细胞转移中对心肌再生的潜力.
  • 在心力衰竭的小鼠模型中评估环林A2基因转移的治疗疗效.

主要方法:

  • 易斯大鼠心肌梗塞后的腺核病毒载体向心肌梗塞周围区域输送环林A2.
  • 对心肌细胞细胞循环激活标记物的评估 (PCNA,Ki-67,BrdU,素-H3).
  • 评估心肌功能,血液动力学和心室几何学.

主要成果:

  • 成功诱导心肌细胞细胞循环激活和由环林A2.2进行线粒分裂.
  • 增加边界区域肌纤维密度和改善心室壁厚度.
  • 显著改善心脏输出,收缩率 (Pmax,最大dP/dt) 和输出功率.

结论:

  • 赛克林A2基因转移有效诱导心肌细胞的增殖,并增强心肌再生.
  • 这种方法证明了环素A2作为心力衰竭的潜在治疗剂的概念证明.
  • 准内生再生通路为心血管疾病提供了一条新的治疗途径.